Tag Archive for: Jazz Pharmaceuticals

The Irish biopharma company did not provide specific data in Thursday’s announcement but said that compared with placebo “there was not a statistically significant decrease” in post-traumatic stress disorder (PTSD) symptoms in patients treated with JZP150. The investigational drug also failed key secondary endpoints, including clinician- and patient-assessed disease severity.

A U.S. appeals court ordered Jazz Pharmaceuticals Inc. on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration’s register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc.

The U.S. Food and Drug Administration (FDA) is planning to make recommendations on how to regulate the use of popular cannabis compound CBD in food and supplements, the Wall Street Journal reported on Tuesday, citing agency officials.

Jazz Pharmaceuticals plc announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex (cannabidiol) oral solution reported improvements in patients’ seizure and non-seizure outcomes across all age groups.

Jazz Pharmaceuticals and Zymeworks Inc. entered into a $50 million licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2, the companies announced Wednesday.

Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2022 Prix Galien USA Award nominees for “Best Biotechnology Product,” “Best Pharmaceutical Agent,” and “Best Medical Technology.” Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.

Initial results from Jazz Pharmaceuticals’ Phase III study on Sativex (JZP378) for the treatment of multiple sclerosis failed to achieve the primary endpoint of an improvement in muscle tone.